Risk of MGUS, a multiple myeloma precursor, in relation to food and beverage intake in the National Health and Nutrition Examination Survey (NHANES).

Authors

null

Janine Joseph

Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Janine Joseph , Li Tang , Jens Hillengass , Ola Landgren , Saad Zafar Usmani , Alexander M. Lesokhin , Kirsten B. Moysich , Urvi A Shah

Organizations

Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Center, Buffalo, NY, UM/Sylvester Comprehensive Cancer Center, Miami, FL, Memorial Sloan Kettering Cancer Center, New York, NY

Research Funding

No funding received
None.

Background: Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder (PCD) with a prevalence of 3% in adults over age 50. The annual risk of progression to multiple myeloma (MM) is 1%. Although one cohort study in Caucasians reported that diets low in certain plant-based foods were associated with MGUS (Thordardottir et al. 2018), research on diet and MGUS in a more diverse population is scarce. Given that diet can vary greatly across ethnic/racial groups, we conducted a population-based study with multiple races and ethnicities. Methods: Using the National Health and Nutrition Examination Survey (NHANES), we conducted a case-control study in 373 individuals with MGUS and 1,406 controls frequency matched on age, body mass index, NHANES cycle, sex, and race. Diet was characterized by one 24-hour dietary recall, with gram intake of individual foods and beverages aggregated into groups. MGUS status was determined by blood screening. Unconditional multivariable logistic regressions were used to model associations between MGUS and intake, with odds ratios and 95% confidence intervals reported for the highest quantile of intake. Results: Daily intake of several food and beverage groups were significantly associated with MGUS, low-risk MGUS (LRMGUS) or intermediate/high-risk MGUS (IHRMGUS). Whole-grain bread, oats, and rice; fruits and vegetables; tomatoes; and cruciferous vegetables were associated with significantly lower risk (28-78%). Sugar- and artificially sweetened beverages were associated with significantly higher risk (34-113%). Interestingly, there were more significant findings for LRMGUS than IHRMGUS, suggesting potential contributing etiologic differences for LRMGUS and IHRMGUS. Conclusions: Our study shows that low intake of whole grains, fruits and vegetables and high intake of sweetened beverages are associated with MGUS. The identification of dietary risk factors for MGUS in a diverse population is of direct public health relevance. These findings also provide rationale for exploration of mechanistic links between diet and PCDs, such as the ongoing studies NCT04920084, NCT05640843, and NCT05312255.

Food/Beverage GroupMGUS (N=373)LRMGUS (N=158)IHRMGUS (N=180)
Whole-grain bread, oats, rice0.70 (0.48-1.01)10.52 (0.28-0.95)0.89 (0.55-1.42)
Fruits, vegetables0.69 (0.52-0.93)0.67 (0.44-1.03)0.73 (0.49-1.10)
Tomatoes0.72 (0.51-1.00)0.61 (0.36-1.02)0.83 (0.53-1.29)
Cruciferous vegetables0.44 (0.26-0.74)0.77 (0.42-1.41)0.22 (0.09-0.57)
Sugar-sweetened beverages1.34 (1.00-1.78)1.68 (1.13-2.49)1.20 (0.80-1.79)
Soft drinks, sugar-sweetened1.41 (1.01-1.96)1.53 (0.98-2.39)1.42 (0.90-2.23)
Soft drinks, artificially sweet1.55 (1.04-2.33)2.13 (1.28-3.56)1.09 (0.60-2.01)
Cola1.59 (1.14-2.22)1.77 (1.13-2.78)1.47 (0.92-2.33)

1 Odds ratios (95% confidence intervals)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Plasma Cell Disorders

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e20062)

DOI

10.1200/JCO.2023.41.16_suppl.e20062

Abstract #

e20062

Abstract Disclosures